Luxor Capital Group LP Has $4.05 Million Stock Position in Tilray Brands, Inc. $TLRY

Key Points

• Luxor Capital Group LP trimmed its stake in Tilray by 29.9% in Q3, selling 1,000,000 shares and now holds 2,343,000 shares worth about $4.05 million (≈0.21% of the company).
• Analysts have a consensus rating of "Hold" (average target $13.33) amid mixed downgrades/upgrades, while Tilray trades near $6.90 with a market cap of ~$804.0M, a 1‑year range of $3.51–$23.20, and a recent quarterly EPS beat (−$0.02 vs. −$0.14 expected).

Luxor Capital Group LP lowered its position in shares of Tilray Brands, Inc. (NASDAQ:TLRY - Free Report) by 29.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,343,000 shares of the company's stock after selling 1,000,000 shares during the quarter. Luxor Capital Group LP owned 0.21% of Tilray Brands worth $4,053,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in TLRY. Silverlake Wealth Management LLC acquired a new position in Tilray Brands in the 3rd quarter worth approximately $25,000. Oppenheimer & Co. Inc. acquired a new stake in Tilray Brands during the 3rd quarter valued at $25,000. Unified Investment Management purchased a new stake in shares of Tilray Brands in the third quarter valued at $26,000. J.W. Cole Advisors Inc. lifted its holdings in shares of Tilray Brands by 203.2% in the second quarter. J.W. Cole Advisors Inc. now owns 71,890 shares of the company's stock valued at $30,000 after purchasing an additional 48,177 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Tilray Brands in the third quarter worth $30,000. Hedge funds and other institutional investors own 9.35% of the company's stock.

Wall Street Analyst Weigh In

TLRY has been the topic of a number of research analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tilray Brands in a report on Wednesday, January 21st. Zacks Research upgraded Tilray Brands from a "strong sell" rating to a "hold" rating in a research report on Wednesday, February 11th. Roth Mkm lowered their target price on Tilray Brands from $20.00 to $10.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 20th. Wall Street Zen downgraded Tilray Brands from a "hold" rating to a "sell" rating in a report on Saturday, March 7th. Finally, ATB Cormark Capital Markets raised shares of Tilray Brands from a "strong sell" rating to a "hold" rating in a research report on Wednesday, December 10th. One research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $13.33.

Tilray Brands Trading Up 0.1%

NASDAQ TLRY opened at $6.90 on Tuesday. The company has a current ratio of 2.81, a quick ratio of 1.72 and a debt-to-equity ratio of 0.19. Tilray Brands, Inc. has a 1-year low of $3.51 and a 1-year high of $23.20. The firm's fifty day simple moving average is $8.03 and its 200-day simple moving average is $10.69. The company has a market capitalization of $803.92 million, a PE ratio of -0.31 and a beta of 1.95.

Tilray Brands (NASDAQ:TLRY - Get Free Report) last released its quarterly earnings data on Thursday, January 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.12. The firm had revenue of $217.51 million during the quarter, compared to analysts' expectations of $211.15 million. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.During the same quarter last year, the firm earned ($0.03) earnings per share. As a group, sell-side analysts anticipate that Tilray Brands, Inc. will post -0.2 earnings per share for the current fiscal year.

Tilray Brands Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray's product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.